{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T02:40:28Z","timestamp":1769913628969,"version":"3.49.0"},"reference-count":0,"publisher":"Sociedad Espanola de Quimioterapia","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Esp Quimioter"],"published-print":{"date-parts":[[2021,10,25]]},"abstract":"<jats:p>Introduction. Comparative \u201creal life\u201d data on the effectiveness and safety of ceftolozane\/tazobactam (C\/T) versus other regimens (aminoglycosides\/colistin\/combination), in the treatment of multi-resistant (MDR) and extremely resistant (XDR) Pseudomonas aeruginosa (PA), are needed to establish positions. Material and methods. Observational, retrospective study of patients with microbiological confirmation of MDR and XDR PA from July 2016 up to December 2018 in a tertiary hospital. Variables: age, sex, comorbidities, risk factors for multidrug resistance, variables related to infection, source of infection, microorganism and type of sample, antibiotic treatment, clinical cure, microbiological cure, recurrence, mortality on admission and 30 days post-discharge. Patients were classified according to received antibiotic treatment, C\/T or aminoglycosides\/colistin\/combination Results. A total of 405 patients with PA MDR and XDR infection (73.1% men, mean age 63 \u00b1 15 years) were studied. An 87.1% of PA XDR and a 12.9% MDR were observed. All patients received C\/T as targeted therapy and in the aminoglycosides\/colistin\/combination group were 73.5%. Patients in the C\/T group present worse prognostic factors: septic shock (30.0%) and catheterization (90.0%) (p&lt;0.05). There were not statistically significant differences in microbiological cure (p=0.412), recurrence (p=0.880) and clinical cure (p=0.566). There were not statistically significant differences in mortality at admission (p=0.352) or at 30 days after discharge (p=0.231). A 17.2% of the patients with aminoglycosides\/colistin\/combination had acute kidney injury according to RIFLE criteria and 4.3% with C\/T. Conclusions. The data obtained suggest that there have been no differences in effectiveness (clinical or microbiological cure) in favour of C\/T, although, in the period studied, it was used in most cases in multitreated patients with a worse prognosis. Randomized and prospective studies would be needed to establish an adequate positioning.<\/jats:p>","DOI":"10.37201\/req\/006.2021","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T07:51:22Z","timestamp":1624348282000},"page":"441-449","source":"Crossref","is-referenced-by-count":7,"title":["Utilization study in real clinical practice of ceftolozane\/tazobactam vs aminoglycosides and\/or colistin in the treatment of multirresistant or extremely resistant Pseudomonas aeruginosa"],"prefix":"10.37201","volume":"34","author":[{"given":"Andrea","family":"Pinilla-Rello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Huarte-Lacunza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arantxa","family":"Magall\u00f3n-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Cazorla-Poderoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Pereira-Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"P\u00e9rez-Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itziar","family":"Larrod\u00e9-Leci\u00f1ena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa Mar\u00eda","family":"Mart\u00ednez-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Isabel","family":"L\u00f3pez-Calleja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Servicio de Farmacia, Hospital Universitario Miguel Servet, Zaragoza, Spain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"23328","published-online":{"date-parts":[[2021,6,22]]},"container-title":["Revista Espa\u00f1ola de Quimioterapia"],"original-title":["Estudio de utilizaci\u00f3n en pr\u00e1ctica cl\u00ednica real de ceftolozano\/tazobactam frente a aminogluc\u00f3sidos y\/o colistina en el tratamiento de Pseudomonas aeruginosa"],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T09:23:59Z","timestamp":1635240239000},"score":1,"resource":{"primary":{"URL":"https:\/\/seq.es\/abstract\/rev-esp-quimioter-2021-june-22-2\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,22]]},"references-count":0,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,10,25]]},"published-print":{"date-parts":[[2021,10,25]]}},"URL":"https:\/\/doi.org\/10.37201\/req\/006.2021","relation":{},"ISSN":["0214-3429","1988-9518"],"issn-type":[{"value":"0214-3429","type":"print"},{"value":"1988-9518","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,22]]}}}